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Abstract-We propose and develop a pharmacokinetic model for the quantitative analysis of dose-time- 
cell survival curves devolving from infusions of the murine monoclonal antibody TlOl into patients with 
chronic lymphocytic leukemia and cutaneous T cell lymphoma. Model parameters can reflect dramatic 
patient-to-patient differences, though qualitative differences in model behavior across patients are slight. 
Our model offers tentative explanations for the dynamics of monoclonal antibody therapy in CLL and 
CTCL. 
INTRODUCTION 
The advent of hybridoma technology has made readily available highly specific monoclonal 
antibodies (MoAbs) that may be of significant value for cancer detection and therapy Cl]. Trials 
of MoAb serotherapy have already produced promising results in animal tumor model systems 
[Z, 31; these trials have demonstrated that: (i) MoAbs that are highly selective for tumor cells can 
be produced; (ii) serotherapy may lead to the elimination of resting cells which are not sensitive to 
many chemotherapeutic agents; and (iii) there is typically minimal toxicity associated with MoAb 
therapy. 
Initial clinical studies, conducted by ourselves and others [4-81, suggested that murine MoAbs 
could produce antitumor effects in leukemia patients as well. We subsequently conducted additional 
in uiuo human clinical trials with murine monoclonal antibody TlOl in patients with advanced 
chronic lymphocytic leukemia (CLL) and cutaneous T cell lymphoma (CTCL) at doses of l-500 mg. 
TlOl is an IgG2A of high affinity which binds to a 65,000-67,000 dalton antigen (T65) that is 
expressed by normal and malignant T cells, thymocytes and CLL cells [9]. Although this antigen 
is not tumor specific, it is restricted to the hematopoietic cells listed above. TlOl inhibits the growth 
of CLL and T cells in in vitro colony-forming assays, but does not inhibit other bone marrow 
precursors [lo]. The results of these TlOl trials have been reported in detail elsewhere [l l-143. 
To summarize: (i) TlOl infusions were associated with an acceptable but definite level of toxicity; 
(ii) reproducible but transient antitumor effects were seen; (iii) in vivo binding of TlOl was 
demonstrated on target cells in peripheral blood, bone marrow, cutaneous lesions, tumor masses 
and lymph nodes; (iv) antigenic modulation (decreased T65 expression in the presence of TlOl) 
was seen in all patients; (v) neutralizing antimouse antibodies appeared in about one-third of treated 
patients; and (vi) free serum TlOl levels of several micrograms were achieved with a 24 h infusion 
of 500mg TlOl. 
We describe here a quantitative mathematical model for the immunotherapeutic treatment of 
CLL and CTCL with TlOl devolving from our clinical studies, and thereafter discuss implications 
for future therapeutic protocols. 
DESCRIPTION AND PROPERTIES OF THE MODEL 
As noted above, there are a number of aspects of TlOl MoAb therapy that are of clinical 
relevance. Nevertheless, since optimal implementation of immunotherapeutic regimens will involve 
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the consideration of kinetic phenomena, we focus here on the interplay between cell population 
kinetics and MoAb levels in the body. Our approach is deterministic, utilizing compartmental 
models suggested from our experimental data for the quantitation and prediction of the cell-killing 
behavior associated with the MoAb therapy. 
Let us begin with the cell kinetics of CLL, during a “steady-state” preinfusion period. Stem cells 
or mother cells (M) reside in the marrow and lymph nodes, and give rise to offspring daughter 
cells (D) at some low rate (rate constants k,, k_). Cell surface antigen reactive with TlOl is, 
relatively speaking, either present (+) or absent (-) on the surface membranes of mother cells, 
and their daughters. The daughter cells are eventually eliminated or removed from the central 
circulatory compartment at some rate k,. Typically in CLL there may be an increase (or 
proliferation) of leukemic cells both in the marrow and in the central compartment with time; it 
has been suggested that the accumulation in cells is due not to an increased rate of proliferation 
over that of normal stem cells, rather to a decreased rate of cell death. Thus in terms of our model, 
we have k, + k_ 2 k,, and the population of circulating leukemic cells (D + + D-) may increase 
with time. 
Consider next the dynamics at time of first infusion. We have a continuous infusion of MoAb 
into the central compartment, at rate it). These infusions typically last from 1 to 24 h, a period 
that generally is too short to alter the transformation rate constants k, , k_ and k,. We assume 
instantaneous and uniform mixing of MoAbs throughout the central compartment as well as first- 
order transfer of MoAb between the central and peripheral compartments. In a patient previously 
unexposed to TlOl, free antibody either is irreversibly bound to D+ cells, or to M+ cells, or is 
eliminated via usual protein degradative networks. Besides the usual elimination of daughter cells, 
D+ cells whose surface antigen attracts TlOl antibody are selectively eliminated through the 
reticuloendothelial (RE) system [7]. 
The dynamics of the system subsequent o infusion entail the repopulation of the central 
compartment with malignant cells. Either stem cells may give rise to daughter cells at an augmented 
rate in order to fill the depleted reservoir in the central compartment, or, daughter cells residing 
outside the central compartment enter that compartment in response to a leukostatic feedback 
pathway. 
Let us examine the pharmocokinetics of the system during periods of infusion in greater detail. 
Let t denote time, with start of infusion at t = 0, and let: 
A,-(t) = concentration of free (unbound) TlOl MoAb in the central compartment at time t; 
M,(t) = concentration of free TlOl MoAb in the peripheral compartment; 
L(t) = concentration of D+ cells in the central compartment; 
R,.(t) = average number of free (unbound) receptors on a D+ cell; 
Rb(t) = average number of bound receptors on a D+ cell; 
and 
ki, k, = generic rate constants. 
(Note in particular that we are assuming homogeneity of D+ cells in terms of numbers of cell 
surface receptors for TlOl antibody.) We now consider the model described by the following system 
of differential equations: 
dAd0 
- = i(t) - k,Af - klzA, + k,,Mf - k3AfLRf; 
dt 
dL(t) -= 
dt 
- sb + k,; (2) 
dRXt) - = - k3AfRf 
dt 
(3) 
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and 
‘9 = k3AfRf - k7Rb. (4) 
In equation (1) - k,Af corresponds to first-order elimination of MoAb via protein metabolic 
and degradative networks, including, perhaps binding with antimouse antibodies produced by the 
host in response to the presence of murine antibody; the terms - klZAf and kzl Mr correspond to 
first-order transfer of free MoAb between the central and peripheral compartments; the last term, 
- k,AfLR,, is reflective of an irreversible bimolecular reaction between MoAb and antigen with 
forward rate constant k3. 
With equation (2), we are characterizing elimination of D+ cells via the RE network during 
infusion. Two points merit attention: typically, generation of new D+ cells during the l-24 h period 
of infusion remains relatively constant at a preinfusion rate k6, . and, our Michaelis-Menten-like 
loss function term, -[kqRb/(kS + R,,)], is meant to emulate rapid elimination of cells with large 
numbers of bound antigen-antibody complexes on their cell surfaces, but slow elimination with 
few bound complexes. 
Equation (3) represents the irreversible bimolecular reaction between free MoAb and cell surface 
antigen. Note incidentally that equations (3) and (4) could have been recast in terms of concentrations 
of free receptors Cp (= LR,) and bound receptors Cb (= LRb) in the central compartment, though 
we believe our parameterization to be somewhat more natural. 
Equation (4) incorporates two dynamic processes: the bimolecular reaction between circulating 
MoAb and free receptors, and modulation-that is, the process whereby the presence of antibody 
results in disappearance of reactive surface antigen in Df and M+ cells. Modulation, which may 
represent either internalization or shedding of bound antibody-antigen complexes, can have an 
adverse impact on the efficacy of MoAb therapy, because host effector mechanisms are dependent 
on the amount of TlOl binding to the cell surface at a given point in time [7,15]. 
Numerical solution of the system of equations (l)-(4) is feasible, upon specifying representative 
values for the various parameters and the initial state of the system. Initial values of A,(O) = 0, 
Rb(0) = 0, L(0) = lO”(CTCL)-lO’(CLL) cells/mm3 and R,jO) = 103-lo6 may be reasonably chosen. 
The input function 1 may be scaled to the appropriate dimensions for a given 24 h gram infusion 
of antibody, assuming a volume of distribution of 5.4 1. for a 70 kg man; from binding assays, we 
have found that the forward rate constant k3 may typically vary from 4 x 10’ to 6 x 10’ (M s)-l 
[7161. 
We may derive more realistic representations of the dose-time-cell survival curves for particular 
treatment regimens among certain patients by fitting equations (l)-(4) to these patients’ relevant 
clinical data, accrued during and subsequent o first infusions of TlOl. We have used Mlab [17] 
for this curve fitting. (We note in passing that our system of equations is stiff; hence the Gear-Tu 
method of solution as implemented in Mlab was utilized.) 
Figures 1-4 depict the quantitative effects of a 24 h infusion of 100 mg of TlOl into an individual 
with CLL. We see from Figs 1 and 2 that equation (1) adequately characterizes the time course of 
free TlOl MoAb in the central compartment over the course of first infusion, followed by first- 
order elimination subsequent to cessation of infusion. In Fig. 3, we note that RXt) is a monotonically 
decreasing function of time; Rb(t), on the other hand, is unimodal, first increasing and then 
decreasing, with the rate of decrease in general dependent upon the rapidity of modulation. Figure 
4 depicts the time course of D+ cells in the central compartment of the CLL patient. Two attributes 
of the kinetics of the model are prominent in this display: (1) elimination of D+ cells is quite rapid, 
with a 410g decrease at a constant fractional rate achievable during the first 6 h of infusion; (2) 
repopulation, most likely recruitment of malignant cells from the peripheral compartment, occurs 
over the period of infusion. 
For comparison, in Figs 5-7 we depict the quantitative effects of a 24 h infusion of 1Omg of 
1’101 into an individual with CTCL. Again, equations (1) and (2) adequately characterize the time 
course of free TlOl MoAb in the central compartment; however, none of the parameters in the 
equations can be taken as equivalent across patients. This patient-to-patient heterogeneity is easily 
seen in the post-infusion half-lives for clearance of TlOl, 2.4 h in the CLL patient vs 10.5 h in the 
R. 0. DILLMAN and J. A. KOZIOL 
Time (h) 
Fig. 1. Observed (+) and predicted (-) accretion 
of TlOl monoclonal antibody in the circulatory 
compartment during a 24 h infusion of 1OOmg TlOl 
into a patient with CLL, association constant 
k, = 2.66 x lOs(Ms)-‘. 
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Fig. 3. Predicted levels of free (RJ and bound (RJ 
TlOl cell surface antigen during a 24h infusion of 
TlOl monoclonal antibody. 
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Fig. 2. First-order elimination of TlOl monoclonal 
antibody subsequent to cessation of infusion at r = 24, 
with elimination half-life of 2.4 h (CLL, R, = 1OOmg 
T101/24 h). 
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Fig. 4. Observed (+) and predicted (-) levels of D+ 
cells during a 24 h infusion of monoclonal antibody 
TlOl (CLL). 
CTCL patient. (Our data on other patients bears out this marked heterogeneity, which is not 
attributable to the different diseases.) We found no substantive differences in the time courses of 
RI and R,, between the CLL patient and the CTCL patient; similarly, there is little qualitative 
difference between Figs 4 and 7: elimination of D+ cells was somewhat more rapid in the CTCL 
patient than in the CLL patient; and a slower rate of repopulation was noted. (This latter may 
partially be attributable to the smaller overall tumor burden in CTCL than in CLL, with perhaps 
a correspondingly smaller stem cell pool, or, a decreased propensity to circulation of the tumor 
burden.) 
Let us briefly consider the kinetic phenomena subsequent o infusion. We have little available 
data pertaining to the repopulation of hematopoietic ells in the central compartment following 
discontinuance of infusion and removal of circulating antibody, though we have little reason to 
doubt that repopulation likely .occurs at an early exponential growth rate gradually tapering off 
as a “steady-state” number of cells about equal to the pretreatment level is attained. (In fact, we 
occasionally observe an overshoot, suggestive of stimulation, followed by a decline to the 
pretreatment level.) The Gompertz relative growth curve has been successfully used in situations 
such as this [18,19]. This repopulation phenomenon may represent homeostatic overshoot from 
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Fig. 5. Observed (+) and predicted (-) accretion 
of TlOl monoclonal antibody in the circulatory 
compartment during a 24h infusion of 1Omg TlOl 
into a patient with CLL, association constant 
k, = 9.10 x 10s (M s)-t. 
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Fig. 6. First-order elimination of TlOl monoclonal 
antibody subsequent to cessation of infusion at t = 24, 
with elimination half-life of 10.5 h (CTCL, R, = 10 mg 
Tl01/24 h). 
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Fig. 7. Observed (+) and predicted (-) levels of D+ cells during a 24 h infusion of monoclonal antibody 
TlOl (CTCL). 
other compartments; alternatively, MoAb therapy may actually induce stem cells to cycle actively, 
which could be exploited with more complex therapeutic regimens. 
DISCUSSION 
We have tried to incorporate the salient features of TlOl therapy in CLL and CTCL into our 
mathematical models; nevertheless, certain limitations should be recognized. Undoubtedly the 
models can be further refined to incorporate more complex schemata for the interplay between 
free antibodies and cell-bound receptors [e.g. 203. Our mechanism of cell kill is solely through the 
RE system, as TlOl therapy does not evince either complement-dependent, antibody-mediated 
tumor cell lysis or antibody-dependent, cell-mediated toxicity in vivo. Given the paucity of 
experimental data readily available in the clinical setting, model identifiability and in vivo 
applications of more sophisticated models will remain significant problems. 
It is not surprising, given the heterogeneity of patients with CLL and CTCL, that the model 
parameters cannot be taken as equivalent across patients. Nevertheless, cell populations with 
differing dynamical characteristics can be represented by varying the parameters entering into the 
equations; and, predictions might cautiously be made on the basis of model behavior. For example, 
maximal cell elimination is effectively achieved by 6 h from start of infusion; there is little gain from 
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prolongation of infusion beyond this point. Increasing the infusion rate would indeed decrease the 
nadir of Df cells, though they would not entirely be eliminated. Alternatively, an increased infusion 
rate could counteract a decreased antigen-antibody affinity to maintain a certain level of maximal 
cell elimination. 
The phenomenon of antigenic modulation merits additional comment. In vitro incubation of 
excess monoclonal antibody with target cells results in binding of antibody to the surface antigen. 
In the presence of appropriate effector cells, or complement, the target cells are destroyed. In the 
absence of these, antibody and antigen are internalized and antigen is ultimately re-expressed and 
additional antibody-antigen complexes internalize until no antibody is left in the media. At any 
point in time, if cells are removed and examined for presence of surface antigen, only a small 
amount will be found. However, if the cells are allowed to incubate in media free of the antibody, 
the antigen will be re-expressed at usual levels. 
This same process is evident in vim. Prolonged serum levels of TlOl are eventually associated 
with appearance in the circulation of cells which have very low levels of TlOl on their surface but 
otherwise are phenotypically the same target cells, based on analysis with the monoclonal antibodies. 
Once the TlOl disappears completely, cells in the circulation exhibit the same phenotype and the 
same density and intensity of T65 antigen expression as before treatment. The same phenomenon 
has been observed in the skin of patients with CTCL and in the bone marrow of patients with 
CLL [ll, 133. Our data suggest hat antibody-coated target cells in the circulation are efficiently 
removed by the RE system, but that modulation is occurring in those cells which are outside the 
circulation. These cells which enter the circulation have an insufficient ievel of antibody on their 
surface to induce a removal in the RE system. Thus, therapy beyond a certain dose level, or beyond 
a certain point in time, is apparently wasted in terms of potential tumor cell elimination. 
We should emphasize that equations (l)-(4) most accurately describe the system kinetics during 
initial infusion of MoAb. In our clinical experiences, with subsequent courses of MoAb infusion, 
certain individuals seem to evince increased sensitivity in their RE system to Ab-leukemic cell 
complexes, leading to heightened elimination; yet others produce endogenous antibodies to the 
murine TlOl MoAb which substantially alters the bioavailability and thereby the potency of these 
subsequent infusions. Such factors need to be accounted for in models; but more importantly, the 
combination of host immune response to murine MoAb and the occurrence of modulation have 
significant implications for the frequency and duration of MoAb therapeutic dosage. 
Let us, then, address the potential of MoAb therapy on leukemia. Note that the mechanism of 
antibody-induced cell kill in our model is solely via the RE system: We have no experimental 
evidence of complement-mediated, antibody-dependent, cell-mediated toxicity to leukemic stem 
cells residing in the peripheral compartment (although animal models suggest his can occur). To 
the contrary: MoAb is delivered to the peripheral compartment, where its presence leads perversely 
to modulation. In other words, MoAb infusion with TlOl can be eminently successful in temporarily 
reducing the circulating pool of leukemic cells; but this therapy is not curative. On the other hand, 
we believe a two-pronged approach to immunotherapy could be more effective: initially a brief 
infusion would be given to clear the circulating compartment of leukemic cells, then an infusion of 
MoAb linked to a radioisotope, toxin or chemotherapeutic agent could be given with the hope of 
eliminating the malignant stem cells at the tissue level. (This same principle might similarly apply 
in colon cancer and prostate cancer therapy, situations in which circulating antigen would need to 
be depleted in order to optimize the effect of antibodies directed against carcinoembryonic antigen 
or prostatic acid phosphatase.) Details would need to be worked out: for example, our clinical 
experience suggests that large bolus injections of MoAb can produce untoward reactions with 
certain leukemic patients; consideration might be given to the infusion of a “cocktail” of MoAbs, 
so as to avoid any difficulties with modulation; and the integrity of the MoAb-radioisotope 
complex, and its deliverability to the peripheral compartment, must be assured. Still, we believe 
this method holds promise, and certainly merits further evaluation. Our clinical results should be 
construed not as contraindictive of the efficacy of MoAb therapy, but as providing requisite 
information preliminary to a more sophisticated approach. In fact, dramatic clinical responses to 
monoclonal antibodies have already been reported [S, 6, 211. Further evaluation of passive 
serotherapy logically would include investigation of other antibodies to different antigens (especially 
to non-modulating antigens), cocktails of monoclonal antibodies, utilization of a variety of doses 
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and schedules of administration, and the addition of other immune response modifiers so as to 
augment complement-dependent, antibody-mediated or antibody-dependent, cell-mediated toxicity. 
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